Table 2.
Baseline cohort of patients who survived at 30 days after CVC remval due to suspected CRBSI
| Baseline characteristics | All patients (n = 686) | Survive (n = 567) | Death (n = 119) | RR (95% CI) | P-value |
|---|---|---|---|---|---|
| Male | 503(73.3) | 414(73.0) | 89(74.8) | 1.079(0.740–1.574) | 0.6908 |
| Age 1st quartile (18–51) | 173(25.2) | 154(27.2) | 19(16.0) | 0.563(0.356–0.892) | 0.0106 |
| Age 2nd quartile (52–66) | 174(25.4) | 153(27.0) | 21(17.6) | 0.631(0.407–0.978) | 0.0333 |
| Age 3rd quartile (67–77) | 186(26.9) | 154(27.2) | 32(26.9) | 0.989(0.684–1.429) | 0.9520 |
| Age 4th quartile (78–97) | 153(22.3) | 106(18.7) | 47(39.5) | 2.274(1.650–3.133) | 0.0000 |
| Medical | 400(58.3) | 307(54.1) | 93(78.2) | 2.558(1.702–3.844) | 0.0000 |
| Surgical | 187(27.3) | 172(30.3) | 15(12.6) | 0.385(0.230–0.644) | 0.0001 |
| Traumatology | 99(14.4) | 88(15.5) | 11(9.2) | 0.604(0.337–1.081) | 0.0765 |
| APACHE 1st quartile (2–15) | 195(28.4) | 177(31.2) | 18(15.1) | 0.449(0.280–0.720) | 0.0004 |
| APACHE 2nd quartile (16–19) | 149(21.7) | 126(22.2) | 23(19.3) | 0.863(0.569–1.311) | 0.4863 |
| APACHE 3rd quartile (20–25) | 208(30.3) | 174(30.7) | 34(28.6) | 0.919(0.640–1.321) | 0.6479 |
| APACHE 4th quartile (26–46) | 134(19.5) | 90(15.9) | 44(37.0) | 2.417(1.754–3.331) | 0.0000 |
| Chronic Obstructive Pulmonary Disease | 95(13.8) | 74(13.1) | 21(17.6) | 1.333(0.877–2.026) | 0.1870 |
| Acute Respiratory Distress Syndrome | 76(11.1) | 67(11.8) | 9(7.6) | 0.657(0.348–1.241) | 0.1789 |
| Diabetes mellitus | 121(17.6) | 92(16.2) | 29(24.4) | 1.505(1.040–2.177) | 0.0341 |
| Malignancy | 73(10.6) | 62(10.9) | 11(9.2) | 0.855(0.483–1.514) | 0.5865 |
| Chronic renal failure | 23(3.4) | 14(2.5) | 9(7.6) | 2.358(1.378–4.037) | 0.0050 |
| Corticosteroids | 141(20.6) | 107(18.9) | 34(28.6) | 1.546(1.087–2.198) | 0.0173 |
| Anticoagulant | 203(29.6) | 159(28.0) | 44(37.0) | 1.396(0.999–1.950) | 0.0523 |
| Antibiotics (Combined use [> 2 types]) | 479(69.8) | 382(67.4) | 97(81.5) | 1.905(1.235–2.938) | 0.0022 |
| Tracheostomy | 292(42.6) | 246(43.4) | 46(38.7) | 0.850(0.607–1.190) | 0.3427 |
| Artificial respiration | 437(63.7) | 346(61.0) | 91(76.5) | 1.852(1.249–2.746) | 0.0014 |
| Positive end expiratory pressure | 373(54.4) | 288(50.8) | 85(71.4) | 2.098(1.452–3.032) | 0.0000 |
| CVC removal with new catheter | 484(70.8) | 381(67.2) | 103(86.6) | 2.687(1.629–4.432) | 0.0000 |
| SOFA score 1st quartile (1–8) | 192(28.0) | 174(30.7) | 18(15.1) | 0.459(0.286–0.736) | 0.0006 |
| SOFA score 2nd quartile (9–10) | 186(27.1) | 161(28.4) | 25(21.0) | 0.715(0.476–1.075) | 0.0994 |
| SOFA score 3 rd quartile (11–13) | 177(25.8) | 142(25.0) | 35(29.4) | 1.198(0.840–1.709) | 0.3222 |
| SOFA score 4 th quartile (14–24) | 131(19.1) | 90(15.9) | 41(34.5) | 2.227(1.606–3.087) | 0.0000 |
| CRBSI | 151(22.0) | 126(22.2) | 25(21.0) | 0.942(0.063–1.409) | 0.7714 |
| Pneumonia | 412(60.1) | 337(59.4) | 75(63.0) | 1.134(0.807–1.592) | 0.4673 |
| Abdominal Infection | 19(2.8) | 14(2.5) | 5(4.2) | 1.540(0.712–3.328) | 0.2951 |
| Gastrointestinal infection | 10(1.5) | 8(1.4) | 2(1.7) | 1.156(0.331–4.035) | 0.8234 |
| Soft tissue infections | 13(1.9) | 11(1.9) | 2(1.7) | 0.885(0.245–3.200) | 0.8504 |
| Urinary tract infections | 41(6.0) | 29(5.1) | 12(10.1) | 1.764(1.063–2.927) | 0.0376 |
| Central nervous system infections | 11(1.6) | 11(1.9) | 0 | – | 0.1256 |
| Chest infection | 1(0.1) | 1(0.2) | 0 | – | 0.6466 |
| Biliary tract infection | 2(0.3) | 1(0.2) | 1(0.8) | 2.900(0.718–11.701) | 0.2220 |
| Multiple infections | 126(18.4) | 102(18.0) | 24(20.2) | 1.123(0.750–1.682) | 0.5768 |
| Unknown | 146(21.3) | 124(21.9) | 22(18.5) | 0.839(0.548–1.283) | 0.4125 |
Survive group and death group according to 30 days follow up
APACHE acute physiology and chronic health evaluation, CI confidence interval, CRBSI catheter-related bloodstream infection, CVC central venous catheter, IQR interquartile ranges, RR relative risk, SD standard deviation, SOFA sequential organ failure assessment, PaO2 oxygen partial pressure